Fig. 6

Macrophages lacking CD244 significantly delay tumor growth by increasing memory T cell populations when combined with anti-PD-L1 antibody. (A to D) CD244^fl/fl and CD244^fl/flLysM^cre mice were administered either anti-PD-L1 antibody or the corresponding isotype antibody on 5 and 9 days following B16F10 injection. Analysis of CD8 and CD4 T cells from both the tumor and tumor-draining lymph nodes (TDLN) was conducted 12 days after tumor inoculation. (A) A graph of B16F10 tumor growth. (B) Relative proportion of CD8 and CD4 T cells within the tumor. (C) Illustrated are a representative flow cytometry plots (left), proportion of effector memory (CD62L⁻CD44⁺) and central memory (CD62L⁺CD44⁺) CD8 (middle) and CD4 (right) T cells in the TDLN. (D) Representative flow cytometry plots (left), proportion of PD-1⁺TIGIT⁻ and PD-1⁺TIGIT⁺ cells among total CD8 T cells in the tumor. (E, F) After tumor inoculation, WT mice were co-administered twice with either WT or CD244^−/− BMDMs, along with either isotype antibody or anti-PD-L1 antibody. The growth of B16F10 (E) and LL2 (F) tumors was observed and evaluated in these mice. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant; two-way ANOVA (A, E, F) or one-way ANOVA (B-D). The data represents two (A, C, E, F) and compiled from two (B, D) independent experiments